Alere supports Obama’s National Action Plan to combat Antibiotic-Resistant Bacteria

Alere supports President’s National Action Plan to Combat Antibiotic-Resistant Bacteria
Alere supports President’s National Action Plan to Combat Antibiotic-Resistant Bacteria | Courtesy of
Alere Inc., a rapid diagnostics company, has formally announced its support of President Barack Obama's National Action Plan to combat Antibiotic-Resistant Bacteria.

The National Action Plan provides guidelines for government activities to further improve domestic and international methods and capabilities of preventing and containing outbreaks of antibiotic-resistant diseases. The plan will also improve and apply next-generation diagnostics, vaccines, antibiotics and other therapeutic treatments. Under the plan’s guidelines, health professionals will seek to maintain the effectiveness of antibiotics currently in use.

The plan will go into effect over the upcoming five years.

In support of the Action Plan, Alere has partnered with the Alliance for the Prudent Use of Antibiotics to create Test. Target. Treat. This is an antimicrobial stewardship initiative that will offer equipment and diagnostics methods to help the world become more aware of the dangers of antibiotic-resistant infections. This program will provide support for clinicians as they seek to make the right decision.

"As the global leader in rapid diagnostics for infectious disease, we commend President Barack Obama for establishing a National Action Plan with measurable goals and specific milestones to address the serious threat of antibiotic resistance,” Avi Pelossof, global president of Alere’s Infectious Disease division, said. “We look forward to continuing to work with the Administration on initiatives to promote the development of rapid point-of-care tests that, in turn, help reduce the misuse of antibiotics and unnecessary health care spending.”

Organizations in this Story

Abbott Laboratories

Want to get notified whenever we write about Abbott Laboratories ?
Next time we write about Abbott Laboratories, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.